Published Date : 08 Nov 2022
The global enzyme-linked immunosorbent assay (ELISA) testing market size was exhibited at USD 1.95 billion in 2022 and is predicted to hit USD 4.02 billion by the end of 2030, growing at a CAGR of 6.4% during the forecast period 2022 to 2030.
Enzyme-Linked Immunosorbent Assay (ELISA) also named enzyme immunoassay (EIA) is a plate-based assay procedure for the discovery and evaluation of substances such as antibodies, hormones, proteins, etc. The ELISA has been employed widely as a significant diagnostic instrument in plant pathology, and medicine, as well as a quality-control audit in the biotech and pharmaceutical industries. ELISA assay procedure is based on precise antigen-antibody attachment. The antigen, to be evaluated, is immobilized on a solid surface and then is complexed with an antibody that is linked to an enzyme. Recognition is accomplished by measuring the coupled enzyme activity via incubation with a substrate to manufacture a product that can be calculated. ELISA has usage in various domains such as allergen recognition in the food business, viral infection judgment in the pathology laboratory, and quality controller examinations in pharmaceutical manufacturing. There are numerous types of ELISA namely Direct ELISA, Indirect ELISA, Competitive ELISA, Sandwich ELISA, Portable &Multiple ELISA, In-cell ELISA, and enzyme-linked immunospot assay (ELISPOT).
Factors such as growing incidence of infectious disorders such as hepatitis, dengue, and AIDS, increasing prevalence of neurological disorders, growing geriatric population, high research, and development expenditure of major players, growing per capita healthcare spending, growing incidence of non-communicable diseases, and the emergence of cost-effective technologies are driving the growth of enzyme-linked immunosorbent assay (ELISA) testing market. Increasing focus on laboratory automation and growing R&D activities in monoclonal antibodies (mABs) and biomarkers are further propelling the enzyme-linked immunosorbent assay (ELISA) testing market expansion across the globe. The most important advantage of using ELISA is its specificity and sensitivity with antibodies that are customized for a specific application in disease diagnosis and research. Most researchers and lab operators, commonly use 96-well plate ELISA techniques across the globe as compared to lesser common 384-well and 1536-well plates ELISA.
The automation of ELISA testing has been a constant process since its commencement and already has observed decades of modernization in diagnostic labs. The automation varies from benchtop turnkey workstations, open fully configurable traditional automation platforms, and closed proprietary cartridge or microfluidic-based systems. These automated systems offer improved sensitivity, miniaturization, multiplexing, unparalleled ease of use and fewer errors, and improved productivity. The emerging innovation in ELISA technology has led to increased accuracy, increased sensitivity, and specificity for diagnostic and research applications and thus greater adoption. Also, automated systems are preferred widely by research laboratories for protein quantification in order to meet regulatory compliance.
Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Report Scope
|Market Size In 2022||USD 1.95 Billion|
|Market Size By 2030||USD 4.02 Billion|
|Growth Rate from 2022 to 2030||
CAGR of 6.4%
|Forecast Period||2022 to 2030|
Key Market Players and Strategies:
The major companies operating in the worldwide enzyme-linked immunosorbent assay (ELISA) test market are ZEUS Scientific, Inc., Thermo Fisher Scientific, Inc., R&D Systems, Inc., American Laboratory Products Company (ALPCO), Bio-Rad Laboratories, Inc., BD, BioMérieux SA, and Ortho Clinical Diagnostics, among others.
Increased spending on research and development along with mergers, acquisitions, and collaborations are the important strategies taken up by manufacturers operating in the global enzyme-linked immunosorbent assay (ELISA) testing market. Moreover, leading companies are investing heavily in research for the development of new diagnostic methods. In December 2020, Thermo Fisher Scientific secured CE Mark authorization for the Omni PATH Combi SARS-CoV-2 IgG ELISA test.
The report covers data for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2020, North America dominated the global market with a market share of more than 42%. U.S. signified the highest portion in the North American region mostly due to large investment in ELISA research and the existence of capable scientists. Furthermore, early implementation of the latest diagnostic technologies also contributed to the high market share of the United States.
Europe was the next important market mainly due to the high geriatric population and high expenditure on research and development. The increasing prevalence of non-communicable diseases in the European continent is also anticipated to enhance the demand for enzyme-linked immunosorbent assay (ELISA) testing in the forecast duration. The Asia Pacific region is projected to lead with the highest CAGR of about 7.8% in the estimated duration majorly because of the high frequency of infectious ailments. African, Latin American, and Middle Eastern regions will display perceptible progress.
Major Market Segments Covered:
By Test Type
Buy this Research Report@ https://www.precedenceresearch.com/checkout/1260
You can place an order or ask any questions, please feel free to contact at firstname.lastname@example.org | +1 9197 992 333